Liver as a target for oligonucleotide therapeutics

Journal of Hepatology

Volumn 59, Issue 6, 2013, Pages 1354-1359

  Sehgal, Alfica ^a   Vaishnaw, Akshay ^a   Fitzgerald, Kevin ^a  

^a ALNYLAM PHARMACEUTICALS   (United States)

Author keywords

Antisense; Liver disease; miRNA; Oligonucleotides; siRNA

Indexed keywords

ALPHA 1 ANTITRYPSIN; ANTISENSE OLIGONUCLEOTIDE; APOLIPOPROTEIN B; APOLIPOPROTEIN C3; APTAMER; BLOOD CLOTTING FACTOR 11; BLOOD CLOTTING FACTOR 9A; C REACTIVE PROTEIN; FERROPORTIN; FIBROBLAST GROWTH FACTOR RECEPTOR 4; GROWTH HORMONE RECEPTOR; HEPCIDIN; LIPOPROTEIN A; LOCKED NUCLEIC ACID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; MICRORNA; MICRORNA 122; MIPOMERSEN; MORPHOLINO OLIGONUCLEOTIDE; PLACEBO; PROPROTEIN CONVERTASE SUBTILISIN KEXIN 9; RIBOZYME; SERUM AMYLOID A; SMALL INTERFERING RNA; SUBTILISIN; UNCLASSIFIED DRUG;

5' UNTRANSLATED REGION; ACROMEGALY; ALCOHOLISM; ALTERNATIVE RNA SPLICING; AMYLOIDOSIS; ANEMIA; ARTICLE; ATHEROSCLEROSIS; CHRONIC KIDNEY DISEASE; CUSHING SYNDROME; DRUG TARGETING; ENZYME BINDING; FAMILIAL HYPERCHOLESTEROLEMIA; GENE SILENCING; GENE TARGETING; HEMOCHROMATOSIS; HEMOPHILIA A; HEMOPHILIA B; HEPATIC PORPHYRIA; HEPATITIS C; HUMAN; HYPERCHOLESTEROLEMIA; INFLAMMATORY DISEASE; INJECTION SITE REACTION; LIVER; LIVER CANCER; LOSS OF FUNCTION MUTATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NUCLEOTIDE SEQUENCE; OBESITY; OLIGONUCLEOTIDE THERAPY; PORPHYRIA; PRIORITY JOURNAL; SIDE EFFECT; THROMBOSIS; UPREGULATION;

2′-O-METHOXYETHYL; ALAS1; ANGIOPOIETIN-LIKE 3; ANGPTL3; ANTISENSE; FACTOR VII; FACTOR XI; FVII; FXI; GCGR; GLUCAGON RECEPTOR; HCC; HCV; HEPATITIS C VIRUS; HEPATOCELLULAR CARCINOMA; HOFH; HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA; KINESIN SPINDLE PROTEIN; KSP; LDL; LIVER DISEASE; LNA; LOCKED NUCLEIC ACID; LOW DENSITY LIPOPROTEIN; MICRORNA; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN; MIR; MIRNA; MOE; MTP; OLIGONUCLEOTIDES; PCSK9; PLK1; POLO LIKE KINASE 1; PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9; RISC; RNA INDUCED SILENCING COMPLEX; SAA; SERUM AMYLOID A; SHORT INTERFERING RNA; SIRNA; TMPRSS6; TRANSMEMBRANE PROTEASE SERINE 6; TRANSTHYRETIN; TTR; UNTRANSLATED REGION; UTR; VASCULAR ENDOTHELIAL GROWTH FACTOR; VEGF; Δ-AMINOLEVULINATE SYNTHASE 1;

ANGIOPOIETINS; CHOLESTEROL, LDL; HUMANS; LIVER DISEASES; OLIGONUCLEOTIDES; OLIGONUCLEOTIDES, ANTISENSE;

EID: 84888002594     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2013.05.045     Document Type: Note

References (39)

1. J. Goodchild Therapeutic oligonucleotides Methods Mol Biol 764 2011 1 15
2. B. Ason, J. Castro-Perez, S. Tep, A. Stefanni, M. Tadin-Strapps, and T. Roddy ApoB siRNA-induced liver steatosis is resistant to clearance by the loss of fatty acid transport protein 5 (Fatp5) Lipids 46 2011 991 1003
3. P. Hair, F. Cameron, and K. McKeage Mipomersen sodium: first global approval Drugs 73 2013 487 493
4. T.S. Zimmermann, A.C. Lee, A. Akinc, B. Bramlage, D. Bumcrot, and M.N. Fedoruk RNAi-mediated gene silencing in non-human primates Nature 441 2006 111 114
5. J.D. Horton, J.C. Cohen, and H.H. Hobbs Molecular biology of PCSK9: its role in LDL metabolism Trends Biochem Sci 32 2007 71 77
6. K. Fitzgerald, M. Frank-Kamenetsky, T. Mant, J. Ritter, J. Chiesa, and M. Munasamy Phase I safety, pharmacokinetic, and pharmacodynamic results for ALN-PCS, a novel RNAi therapeutic for the treatment of hypercholesterolemia American heart association's arteriosclerosis Arterioscler Thromb Vasc Biol 32 2012 A67
7. A. Akinc, W. Querbes, S. De, J. Qin, M. Frank-Kamenetsky, and K.N. Jayaprakash Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms Mol Ther 18 2010 1357 1364
8. M.J. Graham, K.M. Lemonidis, C.P. Whipple, A. Subramaniam, B.P. Monia, and S.T. Crooke Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice J Lipid Res 48 2007 763 767
9. K.W. van Dijk, P.C. Rensen, P.J. Voshol, and L.M. Havekes The role and mode of action of apolipoproteins CIII and AV: synergistic actors in triglyceride metabolism? Curr Opin Lipidol 15 2004 239 246
10. Frank-Kamenetsky M, Ftizgerald K. PCSK9 Conference: from gene to therapeutics, Nantes, France; 2010.
11. P.R. Kamstrup, A. Tybjaerg-Hansen, and B.G. Nordestgaard Extreme lipoprotein(a) levels and improved cardiovascular risk prediction J Am Coll Cardiol 61 2013 1146 1156
12. K.W. Sloop, J.X. Cao, A.M. Siesky, H.Y. Zhang, D.M. Bodenmiller, and A.L. Cox Hepatic and glucagon-like peptide-1-mediated reversal of diabetes by glucagon receptor antisense oligonucleotide inhibitors J Clin Invest 113 2004 1571 1581
13. B.A. Zinker, C.M. Rondinone, J.M. Trevillyan, R.J. Gum, J.E. Clampit, and J.F. Waring PTP1B antisense oligonucleotide lowers PTP1B protein, normalizes blood glucose, and improves insulin sensitivity in diabetic mice Proc Natl Acad Sci U S A 99 2002 11357 11362
14. L.M. Watts, V.P. Manchem, T.A. Leedom, A.L. Rivard, R.A. McKay, and D. Bao Reduction of hepatic and adipose tissue glucocorticoid receptor expression with antisense oligonucleotides improves hyperglycemia and hyperlipidemia in diabetic rodents without causing systemic glucocorticoid antagonism Diabetes 54 2005 1846 1853
15. S. Kaptoge, E. Di Angelantonio, L. Pennells, A.M. Wood, I.R. White, and P. Gao C-reactive protein, fibrinogen, and cardiovascular disease prediction N Engl J Med 367 2012 1310 1320
16. Liu Q BC, Dessouki E et al. ISIS-FXIRx, a novel and specific antisense inhibitor of factor XI, caused significant reduction in FXI antigen and activity and increased aPTT without causing bleeding in healthy volunteers. In: 53rd American Society of Hematology annual meeting and exposition; 2011. p. Abs 209.
17. C.K. Dyke, S.R. Steinhubl, N.S. Kleiman, R.O. Cannon, L.G. Aberle, and M. Lin First-in-human experience of an antidote-controlled anticoagulant using RNA aptamer technology: a phase 1a pharmacodynamic evaluation of a drug-antidote pair for the controlled regulation of factor IXa activity Circulation 114 2006 2490 2497
18. D. Adams Hereditary and acquired amyloid neuropathies J Neurol 248 2001 647 657
19. Akshay Vaishnaw, Sara Nochur, Kevin Ftizgerlad, Amy Simon, Gollob J. Advances in oligonucleotide clinical development I. In: 8th Annual meeting of the oligonucleotide therapeutics society; 2012.
20. Guo S, Booten S, et al. Targeting transthyretin for the treatment of transthyretin-associated polyneuropathy using antisense technology. In: 41st Society for neuroscience annual meeting; 2011. p. Abs 424.406.
21. D. Qu, J.H. Teckman, and D.H. Perlmutter Review: alpha 1-antitrypsin deficiency associated liver disease J Gastroenterol Hepatol 12 1997 404 416
22. Alfica Sehgal, Keith S. Blomenkamp, Stuart Milstein, Brian R. Bettencourt, Satya Kuchimanchi, Klaus B. Charisse, et al. Developing an RNAi therapeutic for liver disease associated with alpha-1-antitrypsin deficiency. In: 63rd Annual meeting of the American Association for the Study of Liver Diseases; 2012. p. Abs 188.
23. Shuling Guo, Sheri L. Booten, Gene Hung, Andrew Watt, Keith Blomenkamp, Jeffery H Teckman, et al. Targeting alpha1-antitrypsin for the treatment of A1AT liver disease. In: 8th Annual meeting of the oligonucleotide therapeutics society; 2012. p. Session 6.
24. F. Mattijssen, and S. Kersten Regulation of triglyceride metabolism by angiopoietin-like proteins Biochim Biophys Acta 1821 2012 782 789
25. Abigail Liebow, William Querbes, Tim Racie, Maria Frank-Kamenetsky, Julia Hettinger, Fitzgerald K. Development of ANGPTL3 siRNAs for LDL and triglyceride lowering. In: The 8th annual meeting of the oligonucleotide therapeutics society; 2012. p. 56.
26. Veerle Rottiers, Susanna Obad, Robert McGarrah, Joshua C Black, Robert J Goody, Matthew S Lawrence, et al. Therapeutic targeting of the cholesterol/lipid-regulating miR-33 microRNA family with an 8-mer seed targeting LNA. In: The 8th annual meeting of the oligonucleotide therapeutics society; 2012. p. 78.
27. K.J. Rayner, C.C. Esau, F.N. Hussain, A.L. McDaniel, S.M. Marshall, and J.M. van Gils Inhibition of miR-33a/b in non-human primates raises plasma HDL and lowers VLDL triglycerides Nature 478 2011 404 407
28. S. Shetty, S. Vora, B. Kulkarni, L. Mota, M. Vijapurkar, and L. Quadros Contribution of natural anticoagulant and fibrinolytic factors in modulating the clinical severity of haemophilia patients Br J Haematol 138 2007 541 544
29. Akinc A, Sehgal A, Barros S, Hettinger J, Charisse K, Brodsky J, et al. An RNAi therapeutic targeting antithrombin increases thrombin generation in nonhuman primates. In: 54th American Society of Hematology annual meeting and exposition; 2012. p. Abs 3370.
30. P.J. Schmidt, I. Toudjarska, A.K. Sendamarai, T. Racie, S. Milstein, and B.R. Bettencourt An RNAi therapeutic targeting Tmprss6 decreases iron overload in Hfe-/- mice and ameliorates anemia and iron overload in murine beta-thalassemia intermedia Blood 121 2012 1200 1208
31. Shuling Guo, Carla Casu, Sara Gardenghi, Sheri Booten, Watt A, Freier S, et al. Target TMPRSS6 using antisense technology for the treatment of hereditary hemochromatosis and β-thalassemia. In: 54th ASH Annual meeting and exposition. Atlanta, GA; 2012. p. 481.
32. S. Guo, C. Casu, S. Gardenghi, S. Booten, M. Aghajan, and R. Peralta Reducing TMPRSS6 ameliorates hemochromatosis and beta-thalassemia in mice J Clin Invest 123 2013 1531 1541
33. A. von Drygalski, and J.W. Adamson Iron Metabolism in Man JPEN J Parenter Enteral Nutr 37 2013 599 606
34. Akinc A, Chan-Daniels A, Sehgal A. Targeting the hepcidin pathway with RNAi therapeutics for the treatment of anemia. In: 53rd American Society of Hematology annual meeting and exposition; 2011. p. Abs 688.
35. J. Tabernero, G.I. Shapiro, P.M. Lorusso, A. Cervantes, G.K. Schwartz, and G.J. Weiss First-in-man trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement Cancer Discov 3 2013 406 417
36. F.C. Kalinowski, K.M. Giles, P.A. Candy, A. Ali, C. Ganda, and M.R. Epis Regulation of epidermal growth factor receptor signaling and erlotinib sensitivity in head and neck cancer cells by miR-7 PLoS One 7 2012 e47067
37. C.L. Jopling Regulation of hepatitis C virus by microRNA-122 Biochem Soc Trans 36 2008 1220 1223
38. Robert Persson MH, Bernard D. King, Alice Chen, Karin Zeh, Arthur A. Levin. Pharmacokinetics/pharmacodynamics of miravirsen in treatment-naive patients with genotype 1 chronic HCV infection. In: The 8th annual meeting of the oligonucleotide therapeutics society; 2012. p. 74.
39. T. Umehara, K. Fukuda, F. Nishikawa, M. Kohara, T. Hasegawa, and S. Nishikawa Rational design of dual-functional aptamers that inhibit the protease and helicase activities of HCV NS3 J Biochem 137 2005 339 347